Navigation Links
Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
Date:10/8/2015

ATLANTA, Oct. 8, 2015 /PRNewswire/ -- Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF). The study will be conducted at approximately 60 sites in the United States and European Union, with the EU sites anticipated to begin enrollment early 2016. This landmark clinical trial testing once-daily oral acebilustat treatment over 48 weeks could be the first to establish proof-of-concept for an anti-inflammatory treatment specifically designed to prevent long-term loss of lung function in CF patients. The study will test once daily oral doses of 50 mg and 100 mg acebilustat against placebo on top of background therapy in adult CF patients.

Acebilustat is a first-in-class neutrophil modulator that controls a key inflammatory signal overexpressed in CF and other orphan inflammatory diseases. Acebilustat has been granted orphan drug status for the treatment of CF in the US and the EU.  Results from initial clinical studies in CF patients demonstrated acebilustat's ability to moderate the over-activated inflammatory response in CF, decreasing neutrophils in the lung by 65% and decreasing damaging neutrophil elastase in just two weeks of treatment. Acebilustat did this without jeopardizing the patient's immune response to infection. Importantly, acebilustat treatment is applicable to all CF patients irrespective of their gene mutation and can be used on top of background therapy, including Kalydeco and Orkambi.

The Phase 2 CF trial was designed in conjunction with and supported by a grant from Cystic Fibrosis Foundation Therapies, Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. It will include approximately 30 sites in the US under the oversight of Principal Investigator Dr. Stephen Rowe MD MSPH, Professor at the University of Alabama Birmingham School of Medicine, Director of the Cystic Fibrosis Transition Clinic, and Director of the CFFT Development Network Center for CFTR Detection. Said Dr. Rowe, "CF patients are in desperate need of efficacious and safe anti-inflammatory therapies to control progressive lung disease.  Evaluation of the long term effects of acebilustat is a very important step in that direction, given the favorable Phase 1b results in CF patients."

For more information, please visit http://clinicaltrials.gov/show/NCT02443688.

Logo - http://photos.prnewswire.com/prnh/20150605/221207LOGO


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF)
2. Celtaxsys Has Regulatory Clearance to Begin Phase 2 Trial of Oral CTX-4430 Anti-Inflammatory Therapy for Moderate to Severe Acne Vulgaris - Recruitment of Patients to Commence Immediately
3. Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
4. Greg Duncan Appointed President and Chief Executive Officer of Celtaxsys, Inc.
5. Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
6. Celtaxsys Restructures, Enhances Operational Focus
7. Construction Begins at Genovate Biotechnologys Insulin Ecological Industrial Park in Chinas Changzhou National Hi-tech District
8. NOWDiagnostics Inc. Begins Manufacturing New Point-of-Care Tests Capable of Providing Results in Just Minutes with the Same Reliability as Lab-Based Tests
9. Worlds Most Technologically Advanced Cannabis Cultivation Facility And Laboratory Begins Operating In Delavan, Illinois
10. GSK begins shipping 2015-16 US flu vaccines with focus on customer needs, volume, and speed
11. Aethlon Medical Begins Trading on the Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2018)... ... October 18, 2018 , ... ... million grant by the Centers for Medicare & Medicaid Services (CMS) to develop ... (NPQR) for the CMS’ Quality Payment Program (QPP). ASCP is among seven awardees ...
(Date:10/17/2018)... ... 2018 , ... The OMNISteth™ is the first stethoscope designed ... intuitive adjustments maximize the sound quality and performance during an exam. , The ... body, which automatically adjusts the listening frequency range to the proper level. ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... SightMD (or ... Founders, today announced a strategic partnership with Mid Island Eye Physicians & Surgeons (“Mid ... Bethpage, NY to SightMD’s team of over 50 physicians and 25 convenient locations in ...
Breaking Medicine Technology:
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... part of its mission to provide simple, easy-to-use software for biopharma companies. By ... can now quickly answer those crucial resourcing questions without spending millions of dollars ...
(Date:10/16/2018)... ... October 16, 2018 , ... 13th Annual FDA Inspections ... , The 13th Annual FDA Inspections Summit starts in one week. , ... difficult to keep up. The FDA is focused on any number of new ...
(Date:10/16/2018)... ... 15, 2018 , ... LGC Maine Standards has expanded ... easier linearity and calibration verification. , The kit, in a simulated body ... of the reportable range for Albumin (ALB), Amylase (AMY), Cholesterol (CHOL), Creatinine (CREA), ...
(Date:10/16/2018)... ... October 16, 2018 , ... AutismOne, the ... the proceedings of the 4th Annual International HPV Vaccine Education Symposium. , Presenters ... May 22, 2019, through Friday, May 24, 2019, with a keynote address from ...
(Date:10/13/2018)... ... ... At HEI Health, we believe tomorrow’s healthcare can be made affordable today. HEI Health ... Summit by Marcus Evans. HEI will be hosting an exclusive round table session at ... providers. , Marcus Evans National Healthcare CXO Summit is the premium forum bringing ...
Breaking Medicine News(10 mins):